Cynata Therapeutics Ltd (ASX: CYP) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Cynata Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $49.40 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 179.63 million
Earnings per share -0.088
Dividend per share N/A
Year To Date Return 120.00%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Cynata Therapeutics Ltd (ASX: CYP)
    Latest News

    Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
    Healthcare Shares

    Here's why the Cynata (ASX:CYP) share price is rising today

    This biotechnology company has signed an agreement.

    Read more »

    two hands wearing medical gloves make the shape of a heart, indicating the best healthcare shares on the ASX market
    Healthcare Shares

    Are these 4 ASX medical shares set for a healthy 2021?

    We take a look at how 4 ASX healthcare companies performed last year, and what they might be focusing on…

    Read more »

    jump in asx share price represented by man leaping up from one wooden pillar to the next
    Share Market News

    Cynata Therapeutics share price jumps 14% on COVID-19 trial

    The Cynata Therapeutics Ltd share price leapt 14% this morning as patient enrolment begins on the company’s COVID-19 trial.

    Read more »

    a woman
    Share Gainers

    Why Cynata, Fluence, Food Revolution, & Fortescue are pushing higher

    Cynata Therapeutics Ltd (ASX:CYP) and Fortescue Metals Group Limited (ASX:FMG) are two of four pushing higher despite the market selloff..

    Read more »

    a woman
    Share Gainers

    Why this small cap biotech ASX share zoomed higher on Tuesday

    The Cynata Therapeutics Ltd (ASX:CYP) share price zoomed higher on Tuesday. Here's why...

    Read more »

    a woman
    Share Market News

    Why the Cynata Therapeutics share price is up 10% today

    Here's why the Cynata Therapeutics Ltd (ASX: CYP) share price has jumped 9.8% today

    Read more »

    a woman
    Share Fallers

    Why the Cynata share price crashed 15% lower today

    The Cynata Therapeutics Ltd (ASX:CYP) share price has come under pressure on Thursday and crashed 15% lower...

    Read more »

    a woman
    Share Gainers

    Why Cynata, Medical Developments International, NAB, & Resolute charged higher

    The Cynata Therapeutics Ltd (ASX:CYP) share price and the National Australia Bank Ltd (ASX:NAB) share price are two of four…

    Read more »

    a woman
    Share Gainers

    ASX small caps outperform on the Aussie dollar strength and rate cut bets

    ASX shares at the smaller end of the market are outperforming along with the Australian dollar as the global investors…

    Read more »

    a woman
    Share Gainers

    Cynata Therapeutics share price rockets higher on takeover news

    The Cynata Therapeutics Ltd (ASX:CYP) share price has rocketed higher this morning after revealing that it has received a takeover…

    Read more »

    a woman
    Share Gainers

    These small cap ASX shares are surging higher today

    The Paradigm Biopharmaceuticals Ltd (ASX:PAR) share price is one of three surging higher at the small end of the market…

    Read more »

    a woman
    ⏸️ Investing

    5 ASX shares to build a portfolio around

    Here are my five “must have” stocks picks for those looking to build a well-diversified portfolio that can deliver long-term…

    Read more »

    CYP ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Cynata Therapeutics Ltd

    Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinicaltrials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

    CYP Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    24 May 2024 $0.28 $0.01 3.70% 22,085 $0.28 $0.28 $0.28
    23 May 2024 $0.27 $0.00 0.00% 58,818 $0.29 $0.29 $0.27
    22 May 2024 $0.27 $-0.01 -3.64% 109,259 $0.27 $0.27 $0.27
    21 May 2024 $0.28 $-0.02 -6.90% 109,630 $0.29 $0.29 $0.26
    20 May 2024 $0.29 $0.01 3.57% 84,458 $0.28 $0.29 $0.28
    17 May 2024 $0.28 $0.00 0.00% 5,004 $0.28 $0.28 $0.28
    16 May 2024 $0.28 $0.01 3.70% 82,988 $0.27 $0.28 $0.27
    15 May 2024 $0.27 $0.03 12.24% 217,628 $0.26 $0.29 $0.26
    14 May 2024 $0.25 $0.01 4.17% 105,915 $0.24 $0.25 $0.24
    13 May 2024 $0.24 $0.02 8.89% 290,118 $0.23 $0.25 $0.23
    10 May 2024 $0.23 $-0.01 -4.26% 49,512 $0.24 $0.24 $0.23
    09 May 2024 $0.24 $0.00 0.00% 90,670 $0.22 $0.24 $0.22
    08 May 2024 $0.24 $0.00 0.00% 63,245 $0.23 $0.24 $0.22
    07 May 2024 $0.24 $0.00 0.00% 36,650 $0.24 $0.24 $0.23
    06 May 2024 $0.24 $-0.01 -4.17% 118,739 $0.24 $0.24 $0.22
    03 May 2024 $0.24 $0.01 4.26% 61,892 $0.24 $0.24 $0.24
    02 May 2024 $0.24 $0.01 4.44% 214,841 $0.23 $0.24 $0.23
    01 May 2024 $0.23 $0.02 9.52% 448,745 $0.20 $0.23 $0.20
    30 Apr 2024 $0.21 $0.00 0.00% 121,419 $0.20 $0.21 $0.20
    29 Apr 2024 $0.21 $0.00 0.00% 29,200 $0.21 $0.21 $0.20
    26 Apr 2024 $0.21 $0.00 0.00% 20,743 $0.20 $0.21 $0.20

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    16 May 2024 Geoffrey Brooke Expiry 300,000 $84,000
    Options expired.
    22 Nov 2023 Kilian Kelly Buy 94,143 $12,439
    On-market trade.
    20 Nov 2023 Geoffrey Brooke Issued 500,000 $60,000
    Issue of options.
    20 Nov 2023 Darryl Maher Issued 220,000 $26,400
    Issue of options.
    20 Nov 2023 Kilian Kelly Issued 750,000 $90,000
    Issue of options.
    20 Nov 2023 Janine Rolfe Issued 220,000 $26,400
    Issue of options.
    20 Nov 2023 Paul Wotton Issued 220,000 $26,400
    Issue of options.
    01 Jun 2023 Ross Macdonald Issued 55,813 $11,999
    Placement.
    01 Jun 2023 Ross Macdonald Issued 27,907 $3,767
    Issue of options.
    01 Jun 2023 Geoffrey Brooke Issued 69,767 $9,418
    Issue of options.
    01 Jun 2023 Geoffrey Brooke Issued 139,534 $29,999
    Placement.
    01 Jun 2023 Stewart Washer Issued 69,767 $9,418
    Issue of options.
    01 Jun 2023 Stewart Washer Issued 139,534 $29,999
    Placement.
    01 Jun 2023 Janine Rolfe Issued 116,279 $24,999
    Placement.
    01 Jun 2023 Janine Rolfe Issued 58,140 $7,848
    Issue of options.
    01 Jun 2023 Darryl Maher Issued 50,000 $10,750
    Placement.
    01 Jun 2023 Darryl Maher Issued 25,000 $3,375
    Issue of options.
    01 Jun 2023 Paul Wotton Issued 69,767 $9,418
    Issue of options.
    01 Jun 2023 Paul Wotton Issued 139,534 $29,999
    Placement.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Paul K Wotton Non-Executive Director Jun 2016
    Mr Wotton has joined the Board in June 2016 and was Non-Executive Chair from 28 February 2017 until 18 August 2020. Dr Wotton was the Chief Executive Officer of Obsidian Therapeutics, a clinical stage TIL therapy company based in Cambridge, Massachusetts. Prior to this, he was the Founding President and CEO of Sigilon Inc. Prior to joining Antares, Dr Wotton was the CEO of Topigen Pharmaceuticals and prior to Topigen, he was the Global Head of Business Development of SkyePharma PLC. Dr Wotton held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. Dr Wotton is a member of the Board and Governance Committee of Vericel Corporation (NASDQA: VCEL), a US company developing autologous cellular therapies, Chairman of Kytopen Corp., an MIT startup focused on non-viral transduction technology, independent director at Dimension Inx, a biomaterials platform company and Founder of AvengeBio, a clinical stage immune oncology company focused on ovarian and peritoneal cancers. He was a member of the board of Veloxis Pharmaceuticals AS and Chairman of the Compensation Committee, until its acquisition by Asahi Kasai in February 2020 in a $1.3 billion all cash transaction. He is also past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada. In 2014, he was named New Jersey EY Entrepreneur of the Year in Life Sciences.
    Mr Peter Webse Company Secretary May 2012
    Mr Webse has over 28 years company secretarial experience and is the managing director of Platinum Corporate Secretariat Pty Ltd, a company specialising in providing company secretarial, corporate governance and corporate advisory services.
    Dr Geoffrey E.D Brooke Non-Executive DirectorNon-Executive Chairman May 2019
    Mr Brooke has joined the Board in May 2019 as Non-Executive Director and appointed Chair on 18 August 2020.Dr Brooke co-founded GBS Venture Partners in 1996 and has more than 30 years' venture capital experience. He was formerly President of Medvest Inc.a US-based early stage venture capital group he founded with Johnson & Johnson.Dr Brooke's experience includes company formation and acquisitions as well as public listings on NYSE, NASDAQ and ASX exchanges. From 2009 until 2015,Dr Brooke was an independent director of the Victoria Workcover Authority.
    Mrs Janine Rolfe Non-Executive Director Sep 2022
    Ms Rolfe joined the Board in September 2022. Ms Rolfe brings more than two decades of legal, governance and management experience across various sectors to the Board. In recent years, Ms Rolfe has transitioned to professional non-executive director roles. Ms Rolfe's last executive role was as General Counsel & Company Secretary for S&P/ASX100 Link Group. Prior to that, Ms Rolfe established governance consultancy, Company Matters, where she served at the helm for over a decade and during a period where stakeholders greatly intensified their expectations of Australian companies' governance practices. Previously, she was a legal counsel and company secretary at Qantas Airways and a solicitor at Mallesons Stephen Jaques (now King & Wood Mallesons).
    Dr Darryl Maher Non-Executive Director Jun 2020
    Mr Maher has joined the Board in June 2020. Dr Maher adds global biopharmaceutical and commercialisation capability to the Cynata board, with over 23 years' experience with CSL Limited. CSL is one of the developers of biologic pharmaceutical products and has a market capitalisation of A$130 billion. Dr Maher has had career in pharmaceutical product development, most recently as the former Vice President of R&D and Medical Affairs at CSL Behring Australia where he was responsible for the development of drug products from initiation through to clinical development and to commercialisation. Dr Maher undertook medical training, qualified as a specialist haematologist.
    Dr Kilian Kelly Chief Executive OfficerManaging Director Jul 2023
    --
    Dr Jolanta Airey Chief Medical Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Phillip Asset Management Limited <Bioscience MTF1 AC> 23,588,040 13.13%
    HSBC Custody Nominees Australia Limited 17,172,745 9.56%
    Citicorp Nominees Pty Limited 8,692,216 4.84%
    Fujifilm Corporation 8,088,403 4.50%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 4,248,421 2.37%
    BNP Paribas Nominees Pty Ltd Acf Clearstream 2,730,212 1.52%
    National Nominees Limited 2,500,000 1.39%
    HSBC Custody Nominees Australia Limited GSCO ECA 2,012,007 1.12%
    Dr Ross Alexander Macdonald 2,000,000 1.11%
    Bnp Paribas Noms Pty Ltd <Drp> 1,702,710 0.95%
    Mal Washer Nominees Pty Ltd <Mal Washer Family A/C> 1,559,534 0.87%
    Mr Pawel Rej & Mrs Miroslawa Rej 1,543,036 0.86%
    Mr David Charles Prodrick 1,500,000 0.84%
    Crosswind Trustee Company Limited <Crosswind A/C> 1,500,000 0.84%
    Mr Patrick Anthony Walsh 1,341,790 0.75%
    Mr Jon Nicolai Bjarnason & Mrs Rina Eghoje Bjarnason <Jarck Super Fund A/C> 1,200,000 0.67%
    Dr Maksym Vodyanyk 1,191,658 0.66%
    Helium Management Pty Ltd <Helium SF A/C> 1,135,366 0.63%
    Mr Craig Lawrence Darby 1,110,066 0.62%
    LFT Co 2018 Pty Ltd <Lenz Family A> 1,080,000 0.60%

    Profile

    since

    Note